Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | EPOR | P19235 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ASF1A | Q9Y294 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896056 | 1.00 | LMNA (0.61) | LMNAGAAMAPK14GCGRMAPT | |
| SCHEMBL5896074 | 1.00 | LMNA (0.61) | LMNAGAAMAPK14GCGRMAPT | |
| SCHEMBL5895003 | 0.88 | LMNA (0.76) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5895023 | 0.88 | LMNA (0.76) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5895012 | 0.88 | LMNA (0.76) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5894883 | 0.84 | LMNA (0.67) | LMNAMAPTPOLBALDH1A1MEN1 | |
| SCHEMBL5894892 | 0.84 | LMNA (0.67) | LMNAMAPTPOLBALDH1A1MEN1 | |
| SCHEMBL5894898 | 0.84 | LMNA (0.67) | LMNAMAPTPOLBALDH1A1MEN1 | |
| SCHEMBL5896384 | 0.82 | LMNA (0.70) | LMNAGAAMAPK14MAPTALDH1A1 | |
| SCHEMBL5896831 | 0.82 | LMNA (0.67) | LMNAMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041690-B2 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY, LLC (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060004063-A1 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY, LLC | 2006-01-05 | — | — | US | disclosed |
| EP-1532128-A1 | INHIBITORS OF HCV NS5B POLYMERASE | Pharmacia & Upjohn Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040142980-A1 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004002977-A1 | INHIBITORS OF HCV NS5B POLYMERASE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142980-A1 | Inhibitors of HCV NS5B polymerase | POLRMT, POLR1E, CTDSP1 | LMNA 4118/4885GAA 279/4885MAPK14 3666/4885 |
| US-20060004063-A1 | Inhibitors of HCV NS5B polymerase | POLRMT, EIF5B, POLI | LMNA 4047/4885GAA 233/4885MAPK14 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.